Cadila Healthcare (Cadila)’s recent Para IV filing of Lialda could lead to an incremental earnings per share (EPS) of Rs6-7 upon the launch (patent expiry in 2020) whereas the recently-approved Anastrazole (a breast cancer drug with shared exclusivity) would fetch in a decent Rs2-3 for the same. We think the market is yet to factor [...]
You may also like
{ 0 comments }